engleski

Aspirin Dosing in Cardiovascular Disease

The ADAPTABLE pragmatic clinical trial showed no significant differences in cardiovascular events between the groups that received 81 mg or 325 mg of aspirin among patients with established atherosclerotic cardiovascular disease. However, concerns about the two aspirin doses and their respective efficacy still remain. Dose–weight and dose–height interactions moderate the effects of aspirin on the reduction of cardiovascular events.1 Low aspirin doses (75 to 100 mg) seem to be effective only in patients weighing 50 to 69 kg, with detrimental effects in patients weighing less than 50 kg.

Aspirin ; Dosing ; Cardiovascular disease ; Individual approach

nije evidentirano